HCM - Hutchmed Inmagene begin dosing in phase 1 trial of potential autoimmune disease drug IMG-004
- Hutchmed (China) ( NASDAQ: HCM ) and Inmagene Biopharmaceuticals said the first person based in the U.S. was dosed in a global phase 1 trial of IMG-004.
- Inmagene is developing IMG-004 to potentially treat immunological diseases.
- The study aims to evaluate IMG-004's safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy people.
- Inmagene's Chairman and CEO Jonathan Wang said that IMG-004 was the second drug candidate under the collaboration with Hutchmed which the company successfully advanced into clinical studies this year.
- "Inmagene also expects to submit another investigational new drug (IND) application for a third novel drug candidate in 2022," Wang noted.
For further details see:
Hutchmed, Inmagene begin dosing in phase 1 trial of potential autoimmune disease drug IMG-004